BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, Tanaka H, Matsuura K, Mitsuoka S, Yoshimura N, Oka T, Kudoh S, Hirata K. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol. 2013;7:31-39. [PMID: 23467445 DOI: 10.4137/cmo.s10839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] [Reference Citation Analysis]
2 Diao J, Bao J, Peng J, Mo J, Ye Q, He J. Correlation between NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and increased risk of esophageal cancer: evidence from a meta-analysis. Ther Adv Med Oncol 2017;9:13-21. [PMID: 28203294 DOI: 10.1177/1758834016668682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer. 2015;15:207. [PMID: 25880877 DOI: 10.1186/s12885-015-1227-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
4 Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, Lin L, Lin Z. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer. 2014;14:414. [PMID: 24912939 DOI: 10.1186/1471-2407-14-414] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
5 Cui X, Li L, Yan G, Meng K, Lin Z, Nan Y, Jin G, Li C. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer 2015;15:244. [PMID: 25885439 DOI: 10.1186/s12885-015-1271-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
6 Ding Q, Zhan J. Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther 2013;7:681-9. [PMID: 23946645 DOI: 10.2147/DDDT.S41910] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]